683 Capital Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

683 Capital Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,750	Closed	-$878K	–	244
2020 Q4	$878K	Hold	3,750	–	–	0.04%	123
2020 Q3	$388K	Hold	3,750	–	–	0.03%	113
2020 Q2	$147K	Hold	3,750	–	–	0.01%	128
2020 Q1	$128K	Sell	3,750 -3,000	-44%	-$174K	0.02%	120
2019 Q4	$316K	Sell	6,750 -6,238	-48%	-$410K	0.04%	88
2019 Q3	$1.16M	Sell	12,988 -707	-5%	-$72.5K	0.13%	79
2019 Q2	$1.86M	Hold	13,695	–	–	0.17%	82
2019 Q1	$3.75M	Hold	13,695	–	–	0.34%	60
2018 Q4	$1.73M	Hold	13,695	–	–	0.1%	95
2018 Q3	$5.62M	Hold	13,695	–	–	0.36%	52
2018 Q2	$7.07M	Buy	13,695 +6,195	+83%	+$3.29M	0.48%	43
2018 Q1	$3.45M	Buy	7,500 +50	+0.7%	+$27.3K	0.3%	68
2017 Q4	$4.99M	Buy	7,450 +2,475	+50%	+$1.49M	0.42%	64
2017 Q3	$3.13M	Buy	+4,975	New	+$2.59M	0.33%	64

Other funds holding TCON

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

683 Capital Management's TCON Position: Q1 2021 in Review

683 Capital Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2021, closing a stake of 3,750 shares — an estimated $878K sold.

683 Capital Management first reported a position in TCON in Q3 2017 and held it in 14 quarters. The position peaked at $7.07M in Q2 2018. 42 funds tracked by Wall St. Rank hold TCON as of Q1 2021.

683 Capital Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
683 Capital Management sold 3,750 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $878K.
683 Capital Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 14 quarters.
683 Capital Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $7.07M in Q2 2018.
42 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.